

FOI 3267

2nd September 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Enc FOI 3267

Question 1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Lebrikizumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Phototherapy (UVB or PUVA) - for Atopic Dermatitis only**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

Response:

Please be advised data below relates to current patients as of 12/08/25

- **Abrocitinib** - <5
- **Acitretin** – *data not held
- **Alitretinoin** – *data not held
- **Azathioprine** – data not held
- **Baricitinib** - <5
- **Ciclosporin** – *data not held
- **Dupilumab** - 132

- **Lebrikizumab** - <5
- **Methotrexate** – *data not held
- **Mycophenolate mofetil** – *data not held
- **Pimecrolimus** – *data not held
- **Phototherapy (UVB or PUVA) - for Atopic Dermatitis only** – *data not held
- **Tacrolimus ointment** – *data not held
- **Tralokinumab** - <5
- **Upadacitinib** - 47
- **Nemolizumab** - <5

*This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the ‘world at large’ and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

Response:

- **Abrocitinib** - <5
- **Baricitinib** - 0
- **Dupilumab** - 13
- **Lebrikizumab** – 0
- **Tralokinumab** - 0
- **Upadacitinib** - 13
- **Nemolizumab** - 0

**Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- **6 months to 5**
- **Age 6-11**
- **Age 12-17**
- **Age 18 and above**

Response:

- **6 months to 5** - <5
- **Age 6-11** - <5
- **Age 12-17** - 8
- **Age 18 and above** – 177

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into

account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net